Gene Edit Slashes Cholesterol – One Shot

One shot in the arm may soon rewrite how the body makes cholesterol, not just how it clears it.

Quick Take

A phase 1 trial found a single infusion of VERVE-102 cut PCSK9 protein by up to 88% and LDL cholesterol by up to 62% at the highest dose.
The Eli Lilly-owned therapy uses base editing to permanently switch off the PCSK9 gene, which normally raises bad cholesterol.
Results held steady for at least a year in 15 of the 35 participants studied so far.
Researchers reported no dose-limiting toxic effects, though long-term safety and heart-attack prevention still need proof.

A Single Infusion Aims To Silence A Cholesterol Gene For Good

Doctors have spent decades helping patients lower cholesterol with pills and injections that need refilling for life. VERVE-102 takes a different approach entirely. It uses base editing, a precise gene-editing tool, to make a permanent one-letter change inside liver cells. That change disables the PCSK9 gene, which normally works to raise LDL cholesterol in the blood.

The new data come from a phase 1 study published in The New England Journal of Medicine and led by researcher Vafai and colleagues. The trial gave adults with high cholesterol conditions one intravenous infusion, then tracked their PCSK9 and LDL levels over time. It was open-label and single-arm, meaning every patient knew what they received and there was no comparison placebo group.

At the highest dose tested, PCSK9 protein dropped by 88% and LDL cholesterol fell by 62%, according to the published results. Those numbers rival or beat what strong statin and injectable therapies achieve today, except this treatment requires just one visit instead of a lifetime of prescriptions.

Why Durability Is The Headline Inside The Headline

The most striking detail is not the size of the drop but how long it lasted. Researchers followed 15 participants for at least a full year and found the cholesterol reduction held steady rather than fading. That durability is the entire premise behind calling this a one-time treatment rather than an ongoing therapy.

Eli Lilly, which owns Verve Therapeutics, presented the findings as a late-breaking study at the European Atherosclerosis Society Congress the same day the journal published them. The company’s messaging leans hard into words like “durable” and “one-time treatment,” language that reflects real trial results but also serves a company with a financial stake in the outcome.

The strategy behind VERVE-102 did not come out of nowhere. Scientists have long known that people born with a naturally broken PCSK9 gene tend to have very low cholesterol and unusually low rates of heart disease. That real-world genetic quirk is the entire reason drug makers targeted this gene in the first place.

What Thirty-Five Patients Can And Cannot Tell Us

Thirty-five participants is a meaningful start, but it is still a small group. Trials this size are built to test safety and find the right dose, not to prove a drug prevents heart attacks or strokes. No dose-limiting toxic effects showed up in the reporting so far, which is encouraging, but it does not rule out rare problems that only show up in bigger, longer studies.

It is worth remembering that permanent gene edits cannot be undone if something unexpected surfaces years later. That is a real tradeoff compared to a pill a patient can simply stop taking. Regulators will almost certainly demand years of follow-up data before this moves from research trial to something a family doctor can prescribe.

Gene hacking isn’t science fiction anymore.

Researchers are already editing genes like PCSK9 and ANGPTL3 in humans—and in early trials, a single infusion dropped LDL cholesterol by as much as 62%, with effects still showing up more than a year later.

These are still tiny Phase… pic.twitter.com/wIKBiZLOyU

— Dr. Alex Tatem (@DrAlexTatem) September 11, 2026

Statins, ezetimibe, and existing PCSK9-lowering injections already give doctors effective, well-tested tools with known long-term safety records. For gene editing to earn a place alongside them, it will need to show not just impressive lab numbers but actual reductions in heart attacks, strokes, and deaths over years, not months. That proof is still ahead, not behind.

For now, the science points to a genuinely promising direction rooted in solid biology and real early human data. Cautious optimism, paired with patience for the long trials still to come, is the sensible read here rather than either dismissal or premature celebration.